This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

February 23, 2018

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions
Neoplasms
Interventions
DRUG

BI 754091

Solution for infusion

DRUG

BI 754111

Solution for infusion

Trial Locations (13)

333

Chang Gung Memorial Hospital(Linkou), Taoyuan District

10002

National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

70403

NCKUH, Tainan City

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa

241-8515

Kanagawa Cancer Center, Kanagawa, Yokohama

362-0806

Saitama Cancer Center, Saitama, Kitaadachi-gun

411-8777

Shizuoka Cancer Center, Shizuoka, Sunto-gun

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

135-8550

Japanese Foundation for Cancer Research, Tokyo, Koto-ku

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY